20 August 2019

Adelaide Convention Centre

1100 - 1230

Consumer Advisory Panel Meeting 1 (closed meeting)

1100 - 1230

Study Coordinator Meeting 1

Co-Chairs: Ms Anne Smith & Mr Andy Phay

Clinical research is part of an active global oncology community. Study Coordinators and Research Nurses are vital to the constant development of cancer biology and treatment, and it is essential that they develop knowledge and skills in research development and conduct. The Study Coordinator workshop covers a wide range of topics presented by experts in the field. Attendees will gain a broader insight into the world of oncology research.

Good Clinical Practice/Risk Based Monitoring/NHMRC Safety Reporting Guidelines – Tanya Symons

GI related issues, e.g. biology & pathology of GI cancer – Doctor Matthew Burge

1100 - 1230

Trainee Workshop 1

Chair: Doctor Lorraine Chantrill

Oncology has an active global research community and our understanding of cancer biology and treatment is constantly evolving. It is essential for trainees to develop knowledge and skills in clinical medicine and research methodology. The AGITG Trainee Workshop provides an opportunity for trainees to meet and learn from successful medical, surgical and radiation oncologists as well as scientists, trial co-ordinators and statisticians. Attendees will deepen their understanding of how to conduct successful research and the career opportunities available.

Statistics 101 – Rebecca Asher

Protocol Writing – Professor Chris Karapetis 

Creating an Effective Scientific Poster – Flynn Slattery

1230 - 1300


1300 - 1430

Consumer Advisory Panel Meeting 2 (closed meeting)

1300 - 1430

Study Coordinator Meeting 2

Co-Chairs: Ms Nisha Berthon-Jones & Ms Christine Aiken

Effective Scientific Poster creation – Flynn Slattery

Site Accreditation – where is Australia up to and when can courses and programs be implemented? – Professor Nik Zeps

Health services / implementation research (‘bench to bedside’/translation of research into practice) – Professor John Simes

1300 - 1430

Trainee Workshop 2

Chair: Dr Lorraine Chantrill

Trials and Tribulations – Doctor Amitesh Roy, Doctor Lorraine Chantrill & Professor David Watson

1500 - 1700

Tour of the South Australian Health & Medical Research Institute with Translational Research 101 Lecture

 – Doctor Susan Woods & Associate Professor Dan Worthley

(For Consumer, Study Coordinator & Trainee Delegates Only)

Wednesday 21 August 2019

Adelaide Convention Centre

0700 - 1800

Registration Open

0745 - 0845

Keynote Breakfast Session Sponsored by

Colorectal cancer is one disease but with many faces! – Professor Sharlene Gill

Co-Chairs: Doctor Sharon Pattison & Doctor Hui Li Wong

Colorectal cancer might be a constellation of different diseases with complex biologic dynamics rather than one entity. Clinical research and practice needs to adapt to overcome these complexities. Can we use the available and emerging clinical trial evidence, to identify the most effective and least toxic treatment for the individual patient? This practical session will provide up-to-date information and guidance with an opportunity for question-and-answers. The aim is to enable participants to understand upcoming strategies, clinical and research challenges in the management of colorectal cancer.

0900 - 1030

Opening Plenary Sponsored by

Rare cancers, how can we do it better?

For too long we have been making small incremental improvements in outcomes for rare gastrointestinal cancers using chemotherapy. Are there other more biologically intelligent treatments we could be using in this space? Our opening plenary will explore cutting edge therapies for these cancers.

Co-Chairs: Professor Tim Price & Doctor Lorraine Chantrill

The large fingerprint of Intestinal microbiota in cancer – Professor Christian Jobin

State of the art treatment for biliary tract cancers – Professor Stephen J Wigmore

Combination of radiation and immunotherapy: Fact or fiction. Toxicity verses benefit – Associate Professor Manisha Palta

Panel Discussion


1030 - 1100

Morning Tea

1100 - 1300

AGITG Early Colorectal Cancer Trials

Co-Chairs: Associate Professor Jeanne Tie & TBC

SPAR: A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer – Associate Professor Michael Jameson

ASCOLT: Aspirin for Dukes C and High-Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Placebo Controlled Phase III Trial – PRESENTED WITH ASCOLT Translational – Doctor Mark Jeffery

RENO: Prospective Study of ‘Watch and Wait’ Strategy in Patients with Rectal Cancer who have Developed a Clinical Complete Response with concurrent chemo-radiotherapy: RENO (Rectal Cancer No Operation) – Professor Chris Karapetis

OXTOX: Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study – TBC

AGITG Early Colorectal Cancer Trials Portfolio – How does this fit in to the International Context? – Professor Sharlene Gill 

1300 - 1400


1400 - 1600

AGITG Colorectal Cancer Trials

Co-Chairs: Associate Professor Rachel Wong & Doctor Deme Karikios

MODULATE: Modulation of the tumour microenvironment using either vascular disrupting agents or STAT3 inhibition in order to synergise with PD1 inhibition in microsatellite stable, refractory colorectal cancer – Associate Professor Niall Tebbutt

LIBERATE: A study evaluating liquid biopsies to profile metastatic colorectal cancer – Associate Professor Niall Tebbutt

MONARCC: A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer – Doctor Matthew Burge 

DYNAMIC-Rectal: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study presented with

DYNAMIC-III:  Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Randomised Study – Associate Professor Jeanne Tie

AGITG Colorectal Cancer Trials Portfolio – How does this fit in to the International Context? – Professor Florian Lordick

1400 - 1600

Radiation Oncology Workshop


Co-Chairs: Professor Trevor Leong & Doctor Dominique Lee

International Faculty: Associate Professor Manisha Palta

National Faculty: Associate Professor Eddie Lau

The outcomes for cholangiocarcinomas are poor. Recent interest in exploring new treatment paradigms has seen the emergence of radiotherapy to improve outcomes for patients with cholangiocarcinoma. After a summary of the current imaging modalities in cholangiocarcinoma, this workshop explores the current role of radiotherapy in the management of cholangiocarcinoma. Cases will include radiotherapy in a neoadjuvant, definitive and adjuvant setting.

Presentation: Imaging in Cholangiocarcinoma – Associate Professor Eddie Lau

Discussion of cases – dose, voluming – Doctor Sweet Ping Ng and TBC

1600 - 1645

Afternoon Tea

1645 - 1815

Multidisciplinary Workshop

The Neoadjuvant Approach In Operable Tumours & Other Controversies In Pancreatic Cancer

Chairs: Associate Professor Mustafa Khasraw, Doctor Andrew Oar & Doctor Iain Thomson 

International Faculty Panel: Professor Stephen J Wigmore, Professor Jim Abbruzzese & Associate Professor Manisha Palta

National Faculty Panel: Professor Desmond Yip, Dr Hien Li, Mrs Jan Mumford & TBC

This session will commence with:

  1. State of the art  management of operable pancreatic tumours  Professor Jim Abbruzzese (10 mins)
  2. Pros and cons of primary surgery versus neoadjuvant therapy Professor Stephen J Wigmore and Associate Professor Manisha Palta (10mins each)
  3. Effect of early and intensive nutrition care, delivered via telephone or mobile application, on quality of life in people with upper gastrointestinal cancer Ms Kate Furness (10 min)

This will be followed by brief case presentations

Medical Oncology Case Presentation: Dr Alexander Davis (10min)

Radiation Oncology Case Presentation: Doctor Sweet Ping Ng (10 min)

The panel members will give their perspectives, reflect on their practice and their thoughts regarding future directions in this area with an emphasis on clinical trials to address gaps in our knowledge in the arena. (30 min)

1815 - 2000 

Welcome Reception 

Thursday 22 August 2019

Adelaide Convention Centre

0745 - 0845

Keynote Breakfast Session
The role of SBRT in oligometastatic gastro-intestinal cancerAssociate Professor Manisha Palta

Co-Chairs: Doctor Andrew Oar & Doctor Dominique Lee

Traditional palliative approaches to patients with early metastatic disease has been an area of active research.  Recent randomised evidence has demonstrated an overall survival benefit for SBRT in oligometastatic disease in non-small cell lung cancer.  To date, no randomised trials have been published exploring SBRT in oligometastatic gastrointestinal cancer. This keynote session will discuss the “Who”, “When” and “Why” of SBRT in oligometastatic gastrointestinal cancers and the opportunity for meaningful research in this controversial domain.

0900 - 1100

Translational Science Symposium Sponsored by

Bugs, Drugs and biologicals in GI Cancer

Co-Chairs: Professor Robert Ramsay & Associate Professor Vicki Whitehall

GI cancers develop within the complex environment of the patient where there is a relenting battle between the cancer cells and the host. Pioneers like Paget and Virchow recognized that there are roles played by non-tumour cells we now describe as immune, vessel and other stromal cells. More recent appreciation has emerged of another complex population of organisms that imping upon this battle are those of the microbiota; fungi, bacteria and their phages. Together as intact organisms or products they influence tumour growth, responses to cytotoxic drugs and immunotherapeutics. The translational session traverses these topics of microbiota, chemotherapies and immune modulators as they impact GI cancers.

Microbiota function in cancer initiation and therapeutics – Professor Christian Jobin

The microbiome in upper GI cancer – Professor Emad El-Omar



1100 - 1130

Morning Tea

1130 - 1315

Translational Science Symposium continues

Cutting Edge Translational Science in GI Cancer

Co-Chairs: Professor Oliver Sieber & Doctor Susan Woods

Six experts each present for 15 minutes on a topic of their choice, followed by 15 minute Panel Discussion.

Dr Nick Clemons

Associate Professor Daniel Worthley

Doctor Michael Sorich

Doctor Michael Burchert

Dr Stephen Blake

Panel Discussion






1130 - 1315

Radiation Oncology Workshop
Anal Cancer

Co-Chairs:  Doctor Andrew Kneebone & Doctor Meredith Johnston 

International Faculty: Associate Professor Manisha Palta

National Faculty: Professor Andrew Kneebone, Associate Professor Eddie Lau, Doctor Gina Hesselberg 

Anal cancer is a rare disease but its incidence is rising rapidly. There is a desperate need to improve outcomes as treatments have not changed for nearly thirty years. With advancement of imaging and radiotherapy techniques, the role of personalised treatment is an area of current research.

Response assessment using PET scan, Role of interim PET and 3 month imagingAssociate Professor Eddie Lau

New approaches for anal cancer – role of dose escalation and individualised radiotherapy (ACT5) – Associate Professor Manisha Palta

Case Presentations (1-3 cases) – Doctor Gina Hesselberg

1130 - 1315

Joint Consumer/Study Coordinator Forum 

Co-Chairs: Ms Jan Mumford & Ms Anne Smith

QOL research & Survivorship (including PROs) – Doctor Claudia Rutherford

Exercise physiology & Supportive Care – Associate Professor Haryana Dhillon

Patient compliance with study treatments & adherence to study visit schedule – Mr Grant Baker & Mr Andy Phay

1315 - 1415

Lunch and Poster Review

1415 - 1600

New Concepts Symposium

Co-Chairs: Professor Tim Price & Doctor Katrin Sjoquist

The New Concepts Symposium sponsored by Specialised Therapeutics Australia is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance. A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible. The winner of the Best New Concept Award will receive a $3,500 prize and a framed certificate. The runner up will receive a $1,500 prize and framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report.

1600 - 1630

Afternoon Tea

1630 - 1800

Best of Posters / Fast Forward

Co-Chairs: Professor Stephen Clarke & Professor Robert Ramsay

The AGITG Annual Scientific Meeting accepts abstracts for posters for selection by the Executive Organising Committee.  Posters are displayed in the exhibition area.  Four posters are chosen for presentation in the Best of the Best Session. Each presenter has seven minutes to present with three minutes for questions. Four posters are also chosen for Fast Forward presentation. Each presenter has three minutes to present with two minutes for questions. The AGITG recognises excellence in the Posters and Fast Forward Sessions at each annual meeting. The winning presenter in the Posters Session receives a $3,500 prize and framed certificate. The winning presenter in the Fast Forward session receives $1,500 and a framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report.

1900 - 2000

AGITG 20th Annual Meeting Reception

2000 - 2300

AGITG 20th Annual Meeting Dinner

Friday 23 August 2019

Adelaide Convention Centre

0800 - 0900

Scientific Advisory Committee Meeting (closed meeting)

0900 - 1000

Keynote Breakfast Session
Translating perioperative management of  pancreatic cancer into survival benefits: state-of-the-art and new perspectives Professor James Abbruzzese

Co-Chairs: Associate Professor Mustafa Khasraw & Doctor Melissa Eastgate

New agents, emerging strategies, and optimization of established regimens are changing the delivery and timing of systemic therapy. Has progress in the treatment of pancreas cancer been slow? Are the new strategies likely to result in improved outcomes for patients or is it complicating clinical management in this setting? This session is designed to help place emerging information into the context of clinical trial data in a practical and interactive fashion in order to provide up-to-date information and guidance.


1000 - 1030

Morning Tea

1030 - 1300

AGITG Upper GI Cancer Research

Co-Chairs: Doctor Kate Clarke and TBC

ALT-GIST: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alonefor the first line treatment of advanced gastrointestinal stromal tumour (GIST) Professor Desmond Yip

DOCTOR: A Randomised Phase II Trial of pre-operative cisplatin, 5 fluorouracil and docetaxel, +/-Radiotherapy, based on poor early response to standard chemotherapy for resectable adenocarcinoma of the oesophagus and/or gastro oesophageal junction – COMBINED WITH DOCTOR Translational –  Professor Andrew Barbour

TOPGEAR:  A randomised II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer – Professor Trevor Leong

DYNAMIC-Pancreas: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study – Doctor Belinda Lee

ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gall bladder carcinoma – Doctor Jenny Shannon 

CONTROL NETs: Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study – Associate Professor David Wyld

NABNEC: A Randomised Phase II Study Of nab‐paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas – Associate Professor Mustafa Khasraw

AGITG Upper GI Cancer Research Portfolio – How does this fit in to the International Context? – Professor James Abbruzzese

1300 - 1400


1400 - 1600

Closing Plenary Sponsored by Sponsor - Servier Oncology

Trials and Tribulations in colorectal cancer in 2019

Co-Chairs: Associate Professor Michael Jameson & Professor Steve Ackland

New treatments for colorectal cancer have been sparse in the last few years.  Are there other ways we could look at this diverse group of bowel cancers? Our closing plenary will look at colorectal cancer through different lenses.

International Faculty Panel: Professor Christian Jobin, Professor Florian Lordick, Associate Professor Manisha Palta, Professor Stephen J Wigmore

2018 John Zalcberg OAM Award Recipient Presentation (on appropriate aspects of their area of interest)- Professor John Simes

Registry Trials in CRC and other GI Cancers – Professor Peter Gibbs  

Next challenges in moving from microbiome into clinical integration (opportunities and barriers)Professor Christian Jobin

Hottest topic in colorectal cancerProfessor Florian Lordick

Panel Discussion


Close of ASM


Buses depart to the Airport